Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival

• Main Authors: Lee C., Davies L., Wu Y., Mitsudomi T., Inoue A., Rosell R., Zhou C., Nakagawa K., Thongprasert S., Fukuoka M., Lord S., Marschner I., Tu Y., Gralla R., Gebski V., Mok T., Yang J.
• Format: Journal
• Published: 2017
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85027265241&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/40447
• Institution: Chiang Mai University

Background: We performed an individual patient data meta-analysis to examine the impact of first-generation epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitor (TKI) therapy on overall survival (OS) in advanced non-small cell lung cancer (NSCLC). Methods: Data from trials comparing E...